Clinical Trial: Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07753148) titled 'Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation' on Aug. 03.

Brief Summary: This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation).

The study is looking at:

* What side effects the study drug might cause

* How well the study drug works

* How much of the study drug is in the blood at different times

* If the body makes ant...